Pharmacological regulators of Hippo pathway: Advances and challenges of drug development

Area of Science:

• Cellular signaling
• Molecular biology
• Developmental biology

Background:

• The Hippo signaling pathway is a critical regulator of organ size, tissue regeneration, and bone homeostasis.
• Dysregulation of this pathway, leading to YAP/TAZ activation, is implicated in tumor progression and impaired tissue repair.
• Despite its importance, developing targeted therapies for the Hippo pathway has been historically challenging.

Purpose of the Study:

• To review recent advancements in Hippo signaling pathway modulators.
• To analyze the mechanisms, properties, and in vivo applications of Hippo agonists and antagonists.
• To highlight the therapeutic potential of targeting the Hippo pathway and its downstream effectors like TEAD.

Main Methods:

• Literature review of preclinical and clinical studies on Hippo pathway modulators.
• Analysis of drug discovery efforts targeting YAP/TAZ and TEAD.
• Synthesis of data on regulatory mechanisms and pharmacological profiles of agonists and antagonists.

Main Results:

• Significant progress has been made in developing Hippo signaling pathway agonists and antagonists.
• Several drugs targeting TEAD, a key downstream effector, are in clinical trials with promising results.
• These therapies demonstrate potential for treating cancers, promoting tissue regeneration, and maintaining bone stability.

Conclusions:

• Targeting the Hippo signaling pathway represents a promising therapeutic strategy for various diseases.
• Ongoing research and clinical trials for TEAD inhibitors are advancing the field.
• Further investigation into Hippo pathway modulators could unlock new treatments for organ size control and regenerative medicine.